(Press-News.org) When compared with placebo and other drugs, long-term use of finasteride improves urinary tract symptoms associated with benign prostatic hyperplasia, and reduces disease progression. This conclusion comes from combining the findings of 23 randomized clinical trials that evaluated almost 21,000 men, and is published this month in The Cochrane Library.
Finasteride is frequently given to men who have lower urinary tract symptoms (LUTS) such as frequent voiding at night (nocturia), incomplete emptying, hesitancy, weak stream, and frequent and urgent urination. The symptoms are often caused by prostatic smooth-muscle contractions, and by benign prostatic hyperplasia, a non-cancerous condition in which the prostate gland grows too large.
Like many organs in the body, the size of the prostate is influenced by particular hormones. Dihydrotestosterone is one hormone that increases its size. Finasteride belongs to a class of drugs called 5 alpha reductase inhibitors (5ARI) that reduce prostate size. The full effects of how 5ARIs shrink the prostate are not fully understood, but in part they work by blocking the body's ability to make dihydrotestosterone.
Pharmacologic therapy is the most frequent way of treating men with moderate to severe LUTS and related symptoms. Drugs like finasteride are frequently prescribed to improve LUTS and reduce long-term symptom progression, including the risk for acute urinary retention and the need for surgical intervention. "We needed to determine the effectiveness and harms of finasteride when used on its own or in combination with other therapies, and to compare this with similar drugs," says study leader James Tacklind, who works at the Veterans Affairs Medical Center, Minneapolis, USA.
Finasteride was even more effective at lowering symptom scores when used in combination with doxazosin, an alpha blocker.
"Finasteride seems to be more effective in men with large prostates who use the drugs for at least 1 year, compared to those with small prostates," says Tacklind.
Looking at drug-related adverse effects, the researchers found that they were uncommon in men using finasteride; nevertheless, compared to placebo, men taking it are at slightly increased risk for impotence, erectile dysfunction, decreased libido, and ejaculation disorder.
INFORMATION:
Finasteride reduces symptoms and disease progression associated with enlarged prostates
2010-10-06
ELSE PRESS RELEASES FROM THIS DATE:
Asthma exacerbation and large doses of inhaled corticosteroids
2010-10-06
There is no evidence that increasing the dose of inhaled corticosteroids at the onset of an asthma exacerbation, as part of a patient-initiated action plan, reduces the need for rescue oral corticosteroids. This is the conclusion of work published in The Cochrane Library this month.
There are two mechanisms acting in the lungs of people with asthma. The first is called bronchoconstriction, which is when people's airways constrict during an asthma attack, making it much harder for them to move air in and out of their lungs. The first line treatment for this sort of acute ...
Specific kidney cell could be key in the treatment of kidney failure in diabetes
2010-10-06
Diabetes is the leading reason for kidney failure in the world, resulting in patients requiring dialysis or kidney transplantation. New research has found a cell in the kidney called the podocyte could be the key to understanding why this happens.
The study led by Dr Richard Coward, in the School of Clinical Sciences at the University of Bristol, is published in Cell Metabolism and funded by the Medical Research Council (MRC).
Diabetes related kidney disease has previously been thought to be mainly due to the high levels of sugar in the blood damaging the small blood ...
Building a smaller, lighter future: Understanding polymer behaviors below 1 nanometer
2010-10-06
Kyoto, Japan -- Knowing how to build nanosized assemblies of polymers (long molecular chains) holds the key to improving a broad range of industrial processes, from the production of nanofibers, filters, and new materials to the manufacture of low-energy, nanoscale circuits and devices. A recent paper in Nature Communications sheds light on key behaviors of polymers in specially engineered confined spaces, opening the door to a level of control that has previously been impossible.
Scientists in Japan at Kyoto University and Nagoya University have succeeded in manufacturing ...
MEPs and health professionals call for urgent action to tackle chronic diseases
2010-10-06
Members of the European Parliament are calling on the Presidency of the EU and Member States to tackle urgently the problem of chronic non-communicable diseases that are responsible for 86% of all deaths in the WHO European Region. Their call is supported by an alliance of European health professionals, including ECCO – the European CanCer Organisation – and ESMO – the European Society for Medical Oncology.
After a meeting later today (Tuesday) between MEPs and the Chronic Disease Alliance of ten not-for-profit European organisations that represent over 100,000 health ...
Lifestyle choices and freedoms limit effectiveness of public health interventions
2010-10-06
The Government's ability to intervene directly to protect people's health and well-being has reached its limits in modern society because the health issues of today are closely tied in with individual lifestyle choice and freedoms, a leading academic will say today (October 5).
Public health issues have previously been more amenable to government intervention and included improving sanitation or air quality, or controlling infectious disease. But public health issues today, like smoking, drink and diet, have meant that legislation is a blunt instrument in tackling these ...
Anti-tumor drugs tested by microfluidic device
2010-10-06
Washington, D.C. (October 5, 2010) -- A prototype device developed in Hong Kong will allow laboratory researchers to non-invasively test drugs for their ability to kill tumors by subjecting cancerous cells with different concentration gradients. The new device is built upon microfluidics -- a set of technologies that allows the control and manipulation of fluids at the sub-millimeter scale -- and is described in the American Institute of Physics' journal Biomicrofluidics.
Microfluidic valves within the device, said Hongkai Wu of Hong Kong University of Science and Technology, ...
For future chips, smaller must also be better
2010-10-06
Washington, D.C. (October 5, 2010) -- The explosion of portable communication devices that we enjoy today -- such as cell and smart phones, Bluetooth hands-free units, and wireless Internet networks -- has resulted in part from the development of a wide variety of integrated circuits that create, process and receive the microwave frequencies on which the communication is based.
Continuing demand for higher performance over a wider range of frequencies has shrunk the physical size of circuits and fueled the development of new materials in thin-film forms, tested in detail ...
Model unfolds proteins gently
2010-10-06
Washington, D.C. (October 5, 2010) -- Protein molecules inside cells are constantly reorganizing themselves, driven by very tiny forces exerted by all the other molecules in their crowded environment. Most experimental techniques and theoretical/computational models are necessarily built around much greater driving forces. A new theoretical model reported in the Journal of Chemical Physics investigates the unfolding of fibronectin under gentler conditions.
"Typical models study very fast processes and consume a lot of CPU time," says author Alessandro Pelizzola of the ...
The effects of hydrogen on growing carbon nanotubes
2010-10-06
Washington, D.C. (October 5, 2010) -- Carbon nanotubes -- long, hollow cylinders of carbon billionths of a meter in diameter -- have many potential uses in nanotechnology, optics, electronics, and many other fields. The exact properties of nanotubes depend on their structure, and scientists as yet have little control over that structure, which is determined during the initial formation -- or growth -- of the nanotubes. In fact, says chemical engineer and materials scientist Eray Aydil of the University of Minnesota, "we do not know precisely how the nanotubes grow."
In ...
CAMH selected as field trial site for DSM-5
2010-10-06
For Immediate Release - (October 5, 2010) –Toronto's Centre for Addiction and Mental Health (CAMH) has been selected as one of seven adult field trial sites in North America and the only site in Canada to test proposed diagnostic criteria for the American Psychiatric Association's (APA) fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM). Used by health professionals around the world, DSM is the manual that provides descriptions, symptoms and other criteria for diagnosing mental disorders. CAMH is participating in field trials to help assess ...